Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neutropenia 1Neoplasms 1Mycoses 1Invasive Fungal Infections 1Hematologic Neoplasms 1HIV Infections 1

Interventions

Olanzapine 4Cyclophosphamide 4Voriconazole 3Tranexamic Acid 3Standard of Care 3nilotinib 2letermovir 2fludarabine phosphate 2Zoledronic Acid 2Whole-Body Irradiation 2Practice Guidelines as Topic 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methods 2Imatinib Mesylate 2Educational Status 2Early Intervention, Educational 2Doxorubicin 2Cyclosporins 2Cyclosporine 2venetoclax 1trihexyltetradecylphosphonium chloride 1thymoglobulin 1shengxuening 1posaconazole 1pembrolizumab 1olaparib 1maribavir 1lenvatinib 1ferrous succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Neoplasms × Amphotericin B × Clear all
NCT00750737 2016-09-29

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

M.D. Anderson Cancer Center

Phase 3 Completed
46 enrolled 6 charts
Other hematologic neoplasm

Invasive Fungal Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡